Rosetta Genomics Announces Agreement with MultiPlan for its PersonalizeDx Suite of Testing Services

osetta Genomics Announces Agreement with MultiPlan for its PersonalizeDx Suite of Testing Services Provides access to molecular assays for bladder, lung, prostate and breast cancer for nearly 68 million Americans PRINCETON, N.J. & REHOVOT, Israel--(BUSINESS WIRE)--June 16, 2015-- Rosetta Genomics Ltd. ROSG, a leading developer and provider of microRNA-based molecular diagnostics, announces that PersonalizeDx, a Rosetta Genomics company, has executed a network participation agreement with MultiPlan, Inc. (MultiPlan) for the entire suite of PersonalizeDx testing and services effective July 1, 2015. MultiPlan provides healthcare cost management solutions, including preferred provider networks (PPOs). More than 900,000 healthcare providers participate in MultiPlan's networks, and the company reprices 40 million claims each year. It is estimated that 68 million Americans have access to MultiPlan's networks. In addition to offering regional PPO networks in Wisconsin and the southwest, Multi-Plan offers the leading independent national primary PPO and one of the largest complementary networks in the United States. As a result of this agreement, PersonalizeDx is one of those participating healthcare providers. A PPO is a managed care organization of medical doctors, hospitals and other health care providers that has covenanted with an insurer or a third party administrator (TPA) to provide health care at reduced rates to the insurer's or administrator's clients. "Through our recent acquisition of PersonalizeDx, we now offer a broader menu of molecular and other assays for bladder, lung, prostate and breast cancer patients that enable personalized medicine and help improve patient outcomes. This agreement enhances our ability to offer these valuable testing services to MultiPlan's participating members, providers, payers and TPAs," noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Importantly, this agreement is expected to significantly enhance both the timing and percentage of payments for our testing services, which is a key factor in achieving efficiency in the delivery and distribution of our differentiated content. We look forward to working with the MultiPlan team and to executing additional agreements such as this that broaden access to our growing portfolio of molecular diagnostics and testing services."
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsM&APress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!